Results 141 to 150 of about 1,296 (184)
Ketolides in the treatment of community-acquired respiratory tract infections: A review
Background:The increasing prevalence of resistance to established antibiotics among key respiratory bacterial pathogens highlights a need for new antibacterial agents for the treatment of community-acquired respiratory tract infections (RTIs).
Martin S. Lipsky +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Telithromycin: The First of the Ketolides
Annals of Pharmacotherapy, 2002OBJECTIVE: To review the chemistry, spectrum of activity, pharmacology, clinical efficacy, and safety of telithromycin. DATA SOURCES: A MEDLINE search from 1966 to December 2000 was performed via OVID and PubMed using the following ...
Christopher S, Shain, Guy W, Amsden
openaire +2 more sources
A novel bicyclic ketolide derivative
Bioorganic & Medicinal Chemistry Letters, 2003AbstractFor Abstract see ChemInform Abstract in Full Text.
Ying, Zhao, Qidong, You, Wenbin, Shen
openaire +2 more sources
Recent Developments on Ketolides and Macrolides
Current Medicinal Chemistry, 2001Recent semi-synthetic studies of erythromycin A culminated in the discovery of two ketolide drug candidates, HMR-3647 and ABT-773, for the treatment of community-acquired bacterial infections caused by both macrolide- and beta-lactam-susceptible and -resistant S. pneumoniae, gram negative bacteria, and intracellular atypical pathogens. The discovery of
Y J, Wu, W G, Su
openaire +2 more sources
Novel tethers in ketolide antibiotics
Bioorganic & Medicinal Chemistry Letters, 2007Novel macrolide antibiotics which contain a methylene unit between two nitrogen atoms of carbamate groups or between two nitrogen atoms of one carbamate and one urea group were synthesized using the Curtius rearrangement. Such linkers were shown to be stable under physiological conditions, and the resulting ketolides show potent in vitro and in vivo ...
Takushi, Kaneko +3 more
openaire +2 more sources
Cethromycin: A New Ketolide Antibiotic
Annals of Pharmacotherapy, 2013OBJECTIVE To review the pharmacology, chemistry, microbiology, in vitro susceptibility, mechanism of resistance, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, drug interactions, dosage, and administration of cethromycin, a new ketolide antibiotic.
Mansour, Hanine +3 more
openaire +3 more sources
Telithromycin: The first ketolide antimicrobial
Clinical Therapeutics, 2005Telithromycin is the first of the ketolide antibacterials to receive US Food and Drug Administration (FDA) approval for clinical use. It is approved for the treatment of community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), and acute maxillary sinusitis (AMS) in adults.This article reviews the mechanism of action, in ...
Megan, Nguyen, Eunice P, Chung
openaire +2 more sources
Solithromycin: A novel ketolide antibiotic
American Journal of Health-System Pharmacy, 2017The pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial activity, clinical safety, and current regulatory status of solithromycin are reviewed.Solithromycin is a novel ketolide antibiotic developed for the treatment of community-acquired bacterial pneumonia (CABP).
Buege, Michael J. +2 more
openaire +3 more sources
Ketolides in the treatment of respiratory infections
Expert Opinion on Pharmacotherapy, 2002The ketolides are a new class of macrolides specifically designed to combat respiratory tract pathogens that have acquired resistance to macrolides. The ketolides are semi-synthetic derivatives of the 14-membered macrolide erythromycin A. There are currently two ketolides in the late stages of clinical development in the US (telithromycin [HMR-364 ...
George G, Zhanel, Daryl J, Hoban
openaire +2 more sources
Ketolides: the future of the macrolides?
Current Opinion in Pharmacology, 2002The prevalence of antibiotic resistance in bacterial pathogens associated with community-acquired respiratory tract infections is increasing. Ketolides, semi-synthetic derivatives of erythromycin, overcome the macrolide resistance mechanisms found in Streptococcus pneumoniae and Streptococcus pyogenes, two key pathogens. They also have improved potency
Angela M, Nilius, Zhenkun, Ma
openaire +2 more sources

